{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:25:13Z","timestamp":1777479913091,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2020,2,18]]},"DOI":"10.3233\/cbm-190946","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T12:36:21Z","timestamp":1582029381000},"page":"277-284","source":"Crossref","is-referenced-by-count":8,"title":["High CD38 expression in childhood T-cell acute lymphoblastic leukemia is not associated with prognosis"],"prefix":"10.1177","volume":"27","author":[{"given":"Chan","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di-Ying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Qun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen-Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-190946_ref1","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-M\u00fcnster Group 87","volume":"23","author":"Einsiedel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3233\/CBM-190946_ref2","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children\u2019s Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.3233\/CBM-190946_ref3","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"10.3233\/CBM-190946_ref4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/gcc.22416","article-title":"Pediatric T-cell acute lymphoblastic leukemia","volume":"56","author":"Karrman","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.3233\/CBM-190946_ref5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1189\/jlb.0404262","article-title":"CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines","volume":"77","author":"Sandoval-Montes","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.3233\/CBM-190946_ref6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bjh.14310","article-title":"CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy","volume":"180","author":"Bras","year":"2018","journal-title":"Br J Haematol"},{"key":"10.3233\/CBM-190946_ref7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"10.3233\/CBM-190946_ref8","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2011-06-275610","article-title":"CD38 and chronic lymphocytic leukemia: A decade later","volume":"118","author":"Malavasi","year":"2011","journal-title":"Blood"},{"key":"10.3233\/CBM-190946_ref9","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1158\/0008-5472.CAN-15-0893","article-title":"CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy","volume":"75","author":"Poret","year":"2015","journal-title":"Cancer Res"},{"key":"10.3233\/CBM-190946_ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2013.789510","article-title":"CD38 expression in CLL: A dynamic marker of prognosis","volume":"55","author":"Thompson","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.3233\/CBM-190946_ref11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/CBM-190946_ref12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.3233\/CBM-190946_ref13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/CBM-190946_ref14","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"10.3233\/CBM-190946_ref15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"10.3233\/CBM-190946_ref16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"10.3233\/CBM-190946_ref17","first-page":"41","article-title":"Expression of activation antigens CD38 and CD71 is not clinically important in childhood acute lymphoblastic leukemia","volume":"7","author":"Koehler","year":"1993","journal-title":"Leukemia"},{"key":"10.3233\/CBM-190946_ref18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3324\/haematol.2014.116707","article-title":"Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia","volume":"100","author":"Karawajew","year":"2015","journal-title":"Haematologica"},{"key":"10.3233\/CBM-190946_ref19","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.leukres.2012.03.014","article-title":"Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia","volume":"36","author":"Xu","year":"2012","journal-title":"Leuk Res"},{"key":"10.3233\/CBM-190946_ref20","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/MPH.0000000000001412","article-title":"Minimal residual disease-guided risk restratification and therapy improves the survival of childhood acute lymphoblastic leukemia: Experience from a tertiary children\u2019s hospital in China","volume":"41","author":"Liao","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.3233\/CBM-190946_ref21","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"10.3233\/CBM-190946_ref22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","article-title":"Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: A prospective study","volume":"16","author":"Pui","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.3233\/CBM-190946_ref23","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"key":"10.3233\/CBM-190946_ref24","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"key":"10.3233\/CBM-190946_ref25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","article-title":"Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia","volume":"131","author":"Petit","year":"2018","journal-title":"Blood"},{"key":"10.3233\/CBM-190946_ref26","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/pbc.25582","article-title":"End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia","volume":"62","author":"Parekh","year":"2015","journal-title":"Pediatr Blood Cancer"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-190946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:07:23Z","timestamp":1777385243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-190946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":26,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/cbm-190946","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,18]]}}}